Cyanotic congenital heart disease with malignant paraganglioma

Cyanotic congenital heart disease.

The last 15 years have witnessed a very remarkable change in the attitude of the clinician towards cyanotic congenital heart disease. It is within the memory of many that it was the custom to make a simple diagnosis of congenital heart abnormality with cyanosis, and express the opinion that little or nothing could be done about it. Then there appeared the pioneer work of Abbott and others which...

Cyanotic Congenital Heart Disease

Hematologic Abnormalities in Cyanotic Congenital Heart Disease Patients

Introduction:Patients with cyanotic heart disease may have an acceptable quality of life. However, they are invariably prone to several complications. The aim of this study is search about hematologic abnormalities in cyanotic congenital heart disease patients. Materials and Methods:  In this cross sectional study every cyanotic congenital heart disease patients who was referred to the adult co...

Adult cyanotic congenital heart disease.

The surgical treatment of cyanotic heart disease in the adult poses some technical difficulties in correcting severe anatomical deformities and compromised physiological states over a wide range of conditions. Various abnormalities and their surgical management have been reviewed. Forty-six patients over the age of 18 years have been operated with 10 operative deaths. Of the survivors, 63% have...

Paraganglioma and cyanotic congenital heart disease: The role of tisular hipoxia.

Cyanotic congenital heart disease (CCHD) refers to a group of heart diseases which occur after birth, affect 1/1000 live newborns, and are associated with systemic hypoxia. The incidence of congenital heart disease ranges from 12 to 14/1000 live newborns.1 The different congenital cardiac defects may cause increased pulmonary vascular resistance and pulmonary hypertension, so that approximately...